| Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2 … CN Harrison, N Schaap, AM Vannucchi, JJ Kiladjian, RV Tiu, P Zachee, ... The Lancet Haematology 4 (7), e317-e324, 2017 | 317 | 2017 |
| A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer M Friedlander, KC Hancock, D Rischin, MJ Messing, CA Stringer, ... Gynecologic oncology 119 (1), 32-37, 2010 | 275 | 2010 |
| Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies J Kurtzberg, TJ Ernst, MJ Keating, V Gandhi, JP Hodge, DF Kisor, ... Journal of clinical oncology 23 (15), 3396-3403, 2005 | 200 | 2005 |
| Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models C Hotz, TR Wagenaar, F Gieseke, DS Bangari, M Callahan, H Cao, ... Science translational medicine 13 (610), eabc7804, 2021 | 122 | 2021 |
| A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high‐fat or low‐fat meal in patients with advanced solid tumors EI Heath, EG Chiorean, CJ Sweeney, JP Hodge, JJ Lager, K Forman, ... Clinical Pharmacology & Therapeutics 88 (6), 818-823, 2010 | 115 | 2010 |
| An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+ 1 … BC Goh, NJ Reddy, UB Dandamudi, KH Laubscher, T Peckham, ... Clinical Pharmacology & Therapeutics 88 (5), 652-659, 2010 | 102 | 2010 |
| Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma PY Wen, A Omuro, MS Ahluwalia, HM Fathallah-Shaykh, N Mohile, ... Neuro-oncology 17 (9), 1275-1283, 2015 | 82 | 2015 |
| Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children … JJ Lager, ER Lyden, JR Anderson, AS Pappo, WH Meyer, PP Breitfeld Journal of clinical oncology 24 (21), 3415-3422, 2006 | 80 | 2006 |
| Phase I trial of the pan-PI3K inhibitor pilaralisib (SAR245408/XL147) in patients with chronic lymphocytic leukemia (CLL) or relapsed/refractory lymphoma JR Brown, MS Davids, J Rodon, P Abrisqueta, SN Kasar, J Lager, J Jiang, ... Clinical Cancer Research 21 (14), 3160-3169, 2015 | 71 | 2015 |
| Pazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancers: Initial results of a phase II study M Friedlander, KC Hancock, B Benigno, D Rischin, M Messing, ... Journal of Clinical Oncology 25 (18_suppl), 5561-5561, 2007 | 61 | 2007 |
| Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial JR Brown, M Hamadani, J Hayslip, A Janssens, N Wagner-Johnston, ... The Lancet Haematology 5 (4), e170-e180, 2018 | 58 | 2018 |
| Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumors AR Tan, A Dowlati, SF Jones, JR Infante, J Nishioka, L Fang, JP Hodge, ... The oncologist 15 (12), 1253-1261, 2010 | 56 | 2010 |
| Preliminary results of a phase I study of bevacizumab (BV) in combination with everolimus (E) in patients with advanced solid tumors Y Zafar, J Bendell, J Lager, D Yu, D George, A Nixon, W Petros, R Beci, ... Journal of Clinical Oncology 24 (18_suppl), 3097-3097, 2006 | 42 | 2006 |
| Phase I dose-escalation study of pilaralisib (SAR245408, XL147), a pan-class I PI3K inhibitor, in combination with erlotinib in patients with solid tumors JC Soria, P LoRusso, R Bahleda, J Lager, L Liu, J Jiang, JF Martini, ... The oncologist 20 (3), 245-246, 2015 | 37 | 2015 |
| A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE) KE Bullock, WP Petros, I Younis, HE Uronis, MA Morse, GC Blobe, ... Cancer chemotherapy and pharmacology 67, 465-474, 2011 | 34 | 2011 |
| Phase I Dose‐Escalation Study of Pilaralisib (SAR245408, XL147) in Combination with Paclitaxel and Carboplatin in Patients with Solid Tumors J Wheler, D Mutch, J Lager, C Castell, L Liu, J Jiang, AM Traynor The oncologist 22 (4), 377-e37, 2017 | 29 | 2017 |
| Tumor pharmacokinetics (PK) and pharmacodynamics (PD) of SAR245409 (XL765) and SAR245408 (XL147) administered as single agents to patients with recurrent glioblastoma (GBM): An … TF Cloughesy, PS Mischel, AMP Omuro, M Prados, PY Wen, B Wu, ... Journal of Clinical Oncology 31 (15_suppl), 2012-2012, 2013 | 28 | 2013 |
| Combination Therapies for Treating Hematologic Malignancies Using Pyridopyrimidinone Inhibitors of PI3K/mTOR with Bendamustine and/or Rituximab A DeCillis, J Lager, T Zaks US Patent App. 14/126,181, 2014 | 27 | 2014 |
| Pazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancers: results of a phase II study M Friedlander, KC Hancock, B Benigno, D Rischin, M Messing, ... Annals of Oncology 19, 211-211, 2008 | 26 | 2008 |
| Phase Ib study of safety and pharmacokinetics of the PI3K inhibitor SAR245408 with the HER3-neutralizing human antibody SAR256212 in patients with solid tumors VG Abramson, JG Supko, T Ballinger, JM Cleary, JF Hilton, SM Tolaney, ... Clinical Cancer Research 23 (14), 3520-3528, 2017 | 25 | 2017 |
Danny RischinPeter MacCallum Cancer CentreVerified email at petermac.org
